Masaki Kaibori

59PUBLICATIONS
157CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyMedical virologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (59)

|Jul 28, 2026
Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer.

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 14, 2026
Prediction of microvascular invasion and post-resection prognosis using ADV, AFP-PIVKA-II, and MoRAL scores in hepatocellular carcinoma patients: an international multicenter cohort study with 9,061 patients.

|Apr 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Pageof 10

Frequent Collaborators

39 joint publications

Hisashi Kosaka

29 joint publications

Atsushi Hiraoka

27 joint publications

Kazuhito Kawata

27 joint publications

Takeshi Hatanaka